Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2019-05-07 Capital/Financing Update
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
HeraMED Expands European Distribution Network 2 pages 206.8KB
Capital/Financing Update Classification · 85% confidence The document is an ASX announcement dated 8 May 2019 about HeraMED expanding its European distribution network through a binding Memorandum of Understanding (MOU) with a distributor in Turkey. It discusses commercial agreements, distribution plans, and strategic partnerships but does not contain financial statements, audit information, or detailed financial results. It is a corporate announcement about business development and distribution expansion rather than a financial report or regulatory filing. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to company fundraising, financing activities, or capital structure changes, specifically commercial expansion and distribution agreements.
2019-05-07 English
HeraMED Expands European Distribution Network Clarification 1
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 8 May 2019 regarding HeraMED Limited's expansion of its European distribution network through a binding Memorandum of Understanding with a Turkish distributor. The content focuses on clarifying terms of the MOU, purchase orders, and distribution rights. There are no financial statements, quarterly or annual results, nor any regulatory certifications or voting results. The document is a corporate announcement about a commercial agreement and distribution expansion, not a financial report or regulatory filing. It is not a report publication announcement since it does not mention any report being attached or published. The best fitting category is Capital/Financing Update (CAP) as it relates to business development and commercial agreements impacting company operations and potential revenue streams.
2019-05-07 English
HeraMED begins FDA Approval Process for HeraBEAT 2 pages 170.4KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 29 April 2019 regarding HeraMED submitting a 510K application to the US FDA for approval of its medical device HeraBEAT. It discusses the regulatory approval process and market entry plans but does not contain financial statements, detailed financial data, or comprehensive report content. The document is relatively short (3505 characters) and serves as an update on a regulatory submission and business development milestone. It is not an annual report, earnings release, or detailed financial report. It is also not a certification or officer attestation. The content fits best as a Capital/Financing Update (CAP) because it relates to regulatory approval progress which is critical for the company's capital market activities and future financing or market entry plans. Therefore, the appropriate classification is CAP with high confidence.
2019-04-28 English
March Quarterly Activity Report & Appendix 4C 8 pages 398.2KB
Interim / Quarterly Report Classification · 95% confidence The document is an ASX announcement dated 26 April 2019 providing a quarterly update on HeraMED Limited's business activities and financials for the quarter ended 31 March 2019 (Q1 FY2019). It includes operational highlights, agreements secured, management appointments, and a detailed financial overview including cash flows and expenditure. The document also contains an Appendix 4C Quarterly report, which is a regulatory filing required by the ASX for entities subject to Listing Rule 4.7B, providing a detailed cash flow statement and other financial data for the quarter. The presence of the Appendix 4C quarterly report and the detailed financial data for a quarter strongly indicates this is an Interim / Quarterly Report. The document is about 15,000 characters long, contains substantive financial data and analysis, and is not merely an announcement of a report or a certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR). Q1 2019
2019-04-25 English
Notice of Annual General Meeting and Proxy Form 26 pages 1.0MB
AGM Information Classification · 100% confidence The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and includes detailed information about the time, place, and agenda of the AGM for HeraMED Limited. It contains instructions on voting, proxy appointments, and outlines resolutions to be considered at the meeting, including adoption of the Remuneration Report, election of directors, appointment of auditor, and approval of share issuance and employee incentive schemes. The document does not contain actual financial statements or detailed financial data but serves as a notice and explanatory statement for the AGM. Therefore, it fits the category of AGM Information (AGM-R).
2019-04-25 English
Meerkats Partners for HeraBEATs Australian B2C Launch 2 pages 177.7KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 16 April 2019 about HeraMED partnering with Meerkats for the B2C launch of a product in Australia. It discusses a marketing and distribution partnership, purchase orders, and strategic plans. There is no financial data, no regulatory filings, no voting results, no management changes, no earnings or annual report content. The document is a corporate announcement about a business partnership and product launch strategy. It fits best under Capital/Financing Update (CAP) as it relates to business development and commercial arrangements impacting company capital and sales channels, but not a formal financing event. The document length is 5647 characters, which is sufficient for a full announcement rather than a brief note. Therefore, the classification is CAP with high confidence.
2019-04-15 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.